Ignite Creation Date:
2024-05-06 @ 7:17 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05963087
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-07-27
First Post:
2023-07-19
Brief Title:
Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Organization Data
Organization:
Zhejiang Cancer Hospital
Class:
OTHER
Study ID:
Braf-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Zhejiang Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Wangxia LV
Responsible Party Title:
MD
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Zhejiang Cancer Hospital
Old Name:
None
Old Organization:
None